X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cc-3052 (4) 4
index medicus (4) 4
thalidomide - analogs & derivatives (4) 4
animals (3) 3
female (3) 3
humans (3) 3
in-vitro (3) 3
male (3) 3
thalidomide - pharmacology (3) 3
activation (2) 2
adjuvants, immunologic - pharmacology (2) 2
immunology (2) 2
inhibitory activity (2) 2
mice (2) 2
multiple-myeloma (2) 2
potent inhibitors (2) 2
thalidomide - therapeutic use (2) 2
therapy (2) 2
tumor necrosis factor-alpha - biosynthesis (2) 2
abridged index medicus (1) 1
adjuvants, immunologic - chemistry (1) 1
adjuvants, immunologic - therapeutic use (1) 1
administration, topical (1) 1
adult (1) 1
aged (1) 1
aids/hiv (1) 1
alkali burn (1) 1
alpha production (1) 1
analog (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antibodies, monoclonal - pharmacology (1) 1
antigens, cd - biosynthesis (1) 1
antigens, cd - drug effects (1) 1
antigens, cd - genetics (1) 1
antineoplastic agents - pharmacology (1) 1
aphthous ulcers (1) 1
apoptosis - drug effects (1) 1
apoptosis - physiology (1) 1
bak (1) 1
basic immunology (1) 1
bcl-2 homologous antagonist-killer protein (1) 1
bcl-2-associated x protein (1) 1
bevacizumab (1) 1
biomarkers - metabolism (1) 1
caspase 3 (1) 1
caspase inhibitors (1) 1
caspases - metabolism (1) 1
caspases - physiology (1) 1
cd3 complex - immunology (1) 1
cd4-positive t-lymphocytes - drug effects (1) 1
cd4-positive t-lymphocytes - metabolism (1) 1
cd8-positive t-lymphocytes - drug effects (1) 1
cd8-positive t-lymphocytes - metabolism (1) 1
cell cycle - drug effects (1) 1
cell division - drug effects (1) 1
cells, cultured - drug effects (1) 1
cells, cultured - metabolism (1) 1
chimeric monoclonal antibody (1) 1
chimeric monoclonal-antibody (1) 1
co-stimulation (1) 1
colorectal neoplasms - drug therapy (1) 1
colorectal neoplasms - metabolism (1) 1
colorectal neoplasms - pathology (1) 1
corneal neovascularization (1) 1
corneal neovascularization - drug therapy (1) 1
corneal neovascularization - metabolism (1) 1
co‐stimulation (1) 1
cyclic amp - biosynthesis (1) 1
disease (1) 1
disease models, animal (1) 1
double-blind (1) 1
enzyme-linked immunosorbent assay (1) 1
human macrophages (1) 1
human-immunodeficiency-virus (1) 1
identification (1) 1
immunodeficiency-virus infection (1) 1
immunomodulation (1) 1
immunosuppressive agents - chemistry (1) 1
immunosuppressive agents - pharmacology (1) 1
inflammation (1) 1
injection (1) 1
lenalidomide (1) 1
leukocytes, mononuclear - drug effects (1) 1
leukocytes, mononuclear - immunology (1) 1
lipopolysaccharides - pharmacology (1) 1
lymphocyte activation - drug effects (1) 1
melanoma - drug therapy (1) 1
melanoma - metabolism (1) 1
melanoma - pathology (1) 1
membrane proteins - biosynthesis (1) 1
mice, nude (1) 1
middle aged (1) 1
mitochondrial dysfunction (1) 1
model (1) 1
necrosis factor alpha (1) 1
necrosis-factor-alpha (1) 1
neoplasms - blood (1) 1
neoplasms - therapy (1) 1
oncology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical & Experimental Immunology, ISSN 0009-9104, 10/2002, Volume 130, Issue 1, pp. 75 - 84
Thalidomide (Thd) is clinically useful in a number of conditions where its efficacy is probably related to its anti‐TNF ‐α activity. More recently, Thd has... 
immunomodulation | T lymphocyte | co‐stimulation | thalidomide | TNF | Co-stimulation | Immunomodulation | Thalidomide | MULTIPLE-MYELOMA | ACTIVATION | PHASE-II | IMMUNOLOGY | co-stimulation | POTENT INHIBITORS | CC-3052 | INHIBITORY ACTIVITY | IN-VITRO | THERAPY | IMMUNODEFICIENCY-VIRUS INFECTION | APHTHOUS ULCERS | Adjuvants, Immunologic - pharmacology | Antigens, CD - biosynthesis | Humans | Middle Aged | Tumor Necrosis Factor-alpha - genetics | Male | Thalidomide - pharmacology | Antigens, CD - genetics | Receptors, Interleukin-2 - genetics | Thalidomide - analogs & derivatives | Neoplasms - therapy | Neoplasms - blood | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Adjuvants, Immunologic - therapeutic use | Receptors, Tumor Necrosis Factor - genetics | Cells, Cultured - drug effects | Enzyme-Linked Immunosorbent Assay | Lenalidomide | Receptors, Interleukin-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | CD4-Positive T-Lymphocytes - metabolism | Solubility | Phosphodiesterase Inhibitors - pharmacology | Inflammation | Antigens, CD - drug effects | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | CD8-Positive T-Lymphocytes - drug effects | CD3 Complex - immunology | Lipopolysaccharides - pharmacology | Receptors, Tumor Necrosis Factor - biosynthesis | Aged | Cells, Cultured - metabolism | Thalidomide - therapeutic use | Tumor Necrosis Factor-alpha - biosynthesis | CD4-Positive T-Lymphocytes - drug effects | Receptors, Tumor Necrosis Factor - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Index Medicus | Basic Immunology
Journal Article
Cancer Research, ISSN 0008-5472, 02/2003, Volume 63, Issue 3, pp. 593 - 599
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.